Free tool
FAERS Monitor: Tissueblue
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209569 or its brand name (Tissueblue, Brilliant Blue G). Reports on generic versions are filed under their own applications.
Reports
21
Serious
16
76% of reports
Hospitalization
0
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- disability3
- visual impairment3
- blindness2
- non-infectious endophthalmitis2
- toxic anterior segment syndrome2
- adverse drug reaction1
- drug hypersensitivity1
- endophthalmitis1
- eye disorder1
- eye injury1
- hemianopia1
- impaired quality of life1
- injection site discolouration1
- iris adhesions1
- macular hole1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2020 | 3 |
| 2021 | 4 |
| 2022 | 5 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,138 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| non-infectious endophthalmitis | 2 | 2367.4 | 632.4 | 2,654 |
| iris adhesions | 1 | 1958.2 | 288.6 | 488 |
| toxic anterior segment syndrome | 2 | 1841.3 | 492.1 | 2,065 |
| hemianopia | 1 | 1011.7 | 149.2 | 252 |
| macular hole | 1 | 747.1 | 110.2 | 186 |
| eye injury | 1 | 329.8 | 48.7 | 81 |
| endophthalmitis | 1 | 167.0 | 24.7 | 41 |
| disabilitySignal | 3 | 152.0 | 53.3 | 312 |
| injection site discolouration | 1 | 80.2 | 11.8 | 19 |
| impaired quality of life | 1 | 69.7 | 10.3 | 16 |
| blindness | 2 | 49.2 | 13.2 | 52 |
| eye disorder | 1 | 30.5 | 4.5 | 7 |
| visual impairmentSignal | 3 | 24.2 | 8.5 | 46 |
| adverse drug reaction | 1 | 11.2 | 1.6 | 2 |
| drug hypersensitivity | 1 | 5.2 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.